Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)

A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029837

Enrollment

Unknown

Registered

2020-02-15

Start date

2020-02-17

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)

Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Subjects who meet the all of the following criterion to be elegiable for this study: 1. Meet the requirements of the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)"; 2. Aged 18 to 65 years male or female; 3. The interval from the onset of symptoms to enrollment is within 7days: onset of symptoms is defined as onset of at least one systematic symtom(such as fever(temperature>=37.3 degree C) or shivering,headache,hypodynamia,muscle pain or joint pain) or respiratory symptom(such as cough,pharyngodynia,nasal obstruction,rhinorrhea); 4. Agree to participate in this study and write informed content.

Exclusion criteria

Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU; 2. With pneumonia infected by other virus; 3. With one of following abnormal laboratory parameters( judged per local Laboratory reference range): -ALT or AST>5 ULN or; -ALT or AST >3 ULN, and total bilirubin>2 ULN; 4. Previous or current disease, judged by investigator, may affect his/her participation in this study or outcome of the study, including but not limited to malignant tumor,autoimmune disease,liver and kidney disease, cardiovascular disease(including but not limited to 5. definate history of cadiac diease and arrhythmia and QT prolongation),neurological disease psychiatric disease,active bleeding,serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as HIV,blood system disease, or splenectomy, organ transplantion etc.; 6. Need to receive digitalis for original disease; 7. May be transfered to non-study hospital; 8. Allergy to study drug phosphoric chloroquine; 9. With history of grug abuse and drug dependency; 10. Pregant or lactating women;or planing to be pregnant within 3 months after study; 11. One that the investigator consider not applicable for this study.

Design outcomes

Primary

Measure	Time frame
Time of conversion to be negative of novel coronavirus nucleic acid;	—

Secondary

Measure	Time frame
Remission time of fever;	—

Countries

China

Contacts

Public ContactJinghua Mao

Jingzhou Central Hospital

hbjzyyywlc@163.com+86 071 68497225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026